Target intelligence / Profile preview

Pertussis toxin protein subunit S1 (S1)

Target
S1
Molecular classification
Enzyme (ADP-ribosyltransferase), Bacterial exotoxin component (A/B toxin family), Toxin subunit
01

Overview

Pertussis toxin protein subunit S1 is the catalytically active "A" component of the AB5-type exotoxin produced by Bordetella pertussis, which causes whooping cough. The holotoxin consists of six polypeptides arranged in an A-B structure; S1 forms the A protomer responsible for enzymatic activity while other subunits form a pentameric B oligomer that mediates cell binding. The primary function of S1 is ADP-ribosylation—specifically modifying α-subunits of heterotrimeric Gi/o proteins—thereby disrupting intracellular signal transduction by preventing these G proteins from interacting with their receptors. This leads to increased cAMP levels within host cells and contributes significantly to disease pathology. The unique mechanism has also made it valuable as a biochemical tool for studying G-protein-coupled receptor signaling pathways and as an antigen in acellular vaccines against Bordetella pertussis infection[2][3].

Other names
Pertussis toxin S1 subunitPTX-S1ptxS1
02

Mechanism of action

For drugs or antibodies targeting this molecule (e.g., vaccine-induced antibodies): Neutralization of enzymatic activity by binding to the S1 domain. For pertussis toxin itself as a tool compound: Catalyzes ADP-ribosylation of Gi/o alpha-subunits, locking them in an inactive GDP-bound state and preventing normal G protein-coupled receptor signaling[2][3].

03

Biological functions

ADP-ribosylation of G proteins[2][3]Disruption of signal transduction pathways[3]Modulation of immune responseFacilitation of bacterial pathogenesis
04

Disease associations

Infection (specifically whooping cough/pertussis)[3]Other (used as a tool in cell signaling research)
05

Safety considerations

As a bacterial exotoxin enzyme, it is highly toxic if delivered into humans outside controlled immunization settings.Therapeutic challenges include its potent disruption of host cell signaling pathways leading to systemic effects such as hypoglycemia due to increased insulin release[3].Potential off-target effects if used experimentally.
06

Interacting drugs

Antibodies generated by acellular pertussis vaccines
07

Biomarkers

No specific biomarkers for patient selection or efficacy monitoring related solely to this target. Antibody titers against pertussis toxin are used to assess vaccine response.

Beyond the preview

Go deeper on Pertussis toxin protein subunit S1 (S1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pertussis toxin protein subunit S1 (S1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call